Review Papers Claim by Claim

Visual summary — paper & context

This page visualizes and critiques: Steroid plant hormones: Effects outside plant kingdom (Zhabinskii, Khripach, Khripach, Steroids 2015) and highlights strengths, gaps, and concrete next experiments.

Key positive points (evidence-based)

• Scope: exhaustive collation (~170 refs) across kingdoms — insects, fungi, fish, protozoa and mammals — useful as a field-state snapshot Zhabinskii et al., paper content
• Balanced tone: authors acknowledge contradictions, heterogeneity of methods, and overuse of synthetic analogues; they explicitly call for receptor/mechanism searches in animals rather than over-generalization Paper caveats and recommendations

Principal weaknesses and scientific blindspots

1. Heterogeneous evidence quality — many cited works are small, unpublished reports, patents, local doctoral theses or environmental/toxicology reports (variable peer-review). The review mixes high-quality cell/animal studies with lower-evidence items without formal bias weighting Heterogeneous primary evidence in review
2. Mechanism remains speculative. While the authors propose membrane-level effects or low-level conserved steroid signalling, they provide little direct biochemical evidence linking BS to specific animal receptors or genomic targets; independent literature shows steroid receptors exist in organelles (e.g., mitochondria) and non-genomic pathways that could plausibly mediate cross-kingdom effects but direct binding/activation data for BS in animals are scarce Mitochondrial steroid receptor evidence
3. Over-reliance on synthetic analogues. Many active anti-viral/anticancer hits are 22S,23S diols or halogenated stigmastanes synthesized for convenience; their activity may not reflect natural BS pharmacology or safety in humans — authors note this limitation repeatedly Synthetic-analogue caveat
4. Human data are minimal and small. The human lipid-lowering/athlete/clinical notes cited are small open-label or uncontrolled studies, insufficient to conclude clinical benefit or safety; the review should have graded clinical evidence strength more explicitly Clinical pilot data summarized
5. Potential publication / selection bias. The field contains patents, local theses and reports that may be selectively positive; negative or null results may remain unpublished. The review notes contradictions but cannot quantify publication bias.

Concrete, evidence-focused recommendations (next steps)

• Targeted receptor screens: biochemical ligand-binding and cell-based reporter assays testing natural BS (brassinolide, 24-epibrassinolide) against human nuclear receptor panel (LXR, FXR, PXR, ER/AR variants) and membrane/non-genomic candidates; include mitochondrial fractions given organelle receptor data Mitochondrial receptor assay rationale
• Standardize active compound set: run head-to-head assays using authentic natural BS (purified brassinolide, epibrassinolide, castasterone) vs common synthetic analogues to separate scaffold vs side-chain effects.
• Mechanism-first antiviral/anticancer lead selection: prioritize analogues with high selectivity indices (CC50/EC50) in human primary cells and test synergy with standards (acyclovir, etc.) as some Argentinean studies suggested Antiviral lead observations
• Use rigorous preclinical design: randomized, blinded animal studies with PK/PD, tissue distribution (radiolabeled BS exist in literature), metabolite identification and CYP interactions — the review indicates BS affect liver monooxygenases, so ADME is essential PK and P450 interactions noted

Suggested definitive experiments (concise)

1. In vitro receptor panel binding + transcriptional reporter: compare brassinolide, epibrassinolide, homobrassinolide and top synthetic analogues across human nuclear receptors (LXRα/β, FXR, PXR, ERα/β, AR) and membrane steroid receptor candidates; quantify Kd, EC50, and gene-expression downstream signatures. Pivotal: if natural BS show sub-micromolar binding/activation to a human receptor, cross-kingdom signalling is mechanistically plausible.
2. Mouse in vivo PK/PD + mechanism: administer radiolabeled 24-epibrassinolide, measure tissue concentrations, hepatic P450 modulation, and test lipid outcomes in diet-induced hypercholesterolemic mice with matched vehicle controls and blinded endpoints; include transcriptomics of liver to see LXR/FXR/PXR pathway engagement (would falsify the HMG-CoA reductase mimic hypothesis if no signature appears).
3. Antiviral mechanism-of-action triage: for promising BS analogue, run time-of-addition assays, measure viral entry/translation/late protein synthesis, cytokine profiles in primary human epithelial cells, and plaque reduction synergy with approved antivirals; compare in vivo mouse model with immunocompetent and immunodeficient hosts to distinguish direct antiviral vs immunomodulatory effects.

How well the paper did (scores and quick rationale)

• Novelty: 8 — it reframes plant steroids as cross-kingdom regulators and compiles scattered evidence in one place (timely and provocative) Novel synthesis in review
• Quality: 7 — careful literature collation and frank caveats, but limited critical appraisal of study-level biases and mixing of variable-evidence sources reduces overall rigor.
• Generality: 7 — discussion is broadly relevant to endocrinology/evolutionary biology, but generality depends on future mechanistic validation.
• Usefulness: 7 — useful as a field primer and hypothesis generator for pharmacology and comparative endocrinology, but not a clinical guide.
• Reproducibility: 5 — as a narrative review reproducibility concerns relate to the primary studies; many primary datasets (theses, patents) lack accessible raw data or standardization.
• Explanatory depth: 6 — good conceptual arguments (membrane, non-genomic, evolutionary) but limited molecular/mechanistic depth linking BS to concrete animal receptors.

Blindspots and what would change the conclusion

If carefully controlled receptor-binding assays and robust animal PK/PD studies show no physiologically relevant interaction of natural brassinosteroids with animal receptor systems at achievable tissue concentrations, the hypothesis that BS are general cross-kingdom bioregulators would be substantially weakened. Conversely, demonstration of specific receptor binding/activation or a reproducible therapeutic effect in properly powered, blinded animal/human trials would validate key claims.

Selected supporting/contrasting literature (examples)

• Primary review (this paper): comprehensive synthesis and tables showing biochemical, cellular and small-animal evidence for BS activity outside plants Zhabinskii et al., 2015
• Mitochondrial steroid receptor work (mechanistic plausibility for noncanonical steroid action) Mitochondrial steroid receptor review
• Environmental/analytic methods for steroid detection (relevance when considering human/environment exposure and measurement reliability) Analytical steroid detection methods